Kissei Pharmaceutical and Maruishi Pharmaceutical said on January 7 that their investigational agent difelikefalin (MR13A9) achieved the primary endpoint in a Japan PIII study for the treatment of pruritus in dialysis patients. The study enrolled 178 hemodialysis patients with previously…
To read the full story
Related Article
- Maruishi/Kissei’s Pruritus Med Difelikefalin Filed in Japan
September 29, 2022
- Kissei, Maruishi Join Hands on Opioid Receptor Agonist
March 14, 2017
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





